- CA$45.42m
- CA$41.84m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.8 | ||
| Price to Tang. Book | 10.8 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -133.41% | ||
| Return on Equity | -232.06% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- June 27th, 2011
- Public Since
- May 8th, 2012
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 74,464,675
- Address
- Minus 1 Entry, Ground Floor Of Bldg B, HAIFA, 3200003
- Web
- https://nurexone.com/
- Phone
- +1 4164105297
- Auditors
- BDO & Co.
Upcoming Events for NRX
Similar to NRX
Hemostemix
TSX Venture Exchange
Innovotech
TSX Venture Exchange
KDA
TSX Venture Exchange
Marvel Biosciences
TSX Venture Exchange
Medicure
TSX Venture Exchange
FAQ
As of Today at 21:23 UTC, shares in Nurexone Biologic are trading at CA$0.61. This share price information is delayed by 15 minutes.
Shares in Nurexone Biologic last closed at CA$0.61 and the price had moved by -12.16% over the past 365 days. In terms of relative price strength the Nurexone Biologic share price has underperformed the Toronto Stock Exchange 300 Composite Index by -21.84% over the past year.
The overall consensus recommendation for Nurexone Biologic is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNurexone Biologic does not currently pay a dividend.
Nurexone Biologic does not currently pay a dividend.
Nurexone Biologic does not currently pay a dividend.
To buy shares in Nurexone Biologic you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.61, shares in Nurexone Biologic had a market capitalisation of CA$45.42m.
Here are the trading details for Nurexone Biologic:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NRX
Based on an overall assessment of its quality, value and momentum Nurexone Biologic is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nurexone Biologic is CA$2.84. That is 366.31% above the last closing price of CA$0.61.
Analysts covering Nurexone Biologic currently have a consensus Earnings Per Share (EPS) forecast of -$0.08 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nurexone Biologic. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -3.47%.
As of the last closing price of CA$0.61, shares in Nurexone Biologic were trading -2.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nurexone Biologic PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.61.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nurexone Biologic's management team is headed by:
- James Richardson - CHM
- John Arnold - CFO
- John-Peter Bradford - DRC
- Peter Andrews - IND